令和5年度
巻頭言
2023年度
ライフサイエンス研究所紀要発刊によせて
研究所長
岡田 斉（生化学教室教授）
近畿大学ライフサイエンス研究所は1974 年に大阪狭山キャンパスに設立され、以
来、生命現象の科学的解明と人類の健康及び福祉の増進に寄与してきました。先進的
な分析技術の活用により、特にゲノムの網羅的解析を基盤とした個別化医療とプレシ
ジョン医療の推進に貢献しています。2022 年には難治性神経疾患の診断法、治療法開
発を担う新たな研究室を設置し、革新的な治療法の研究を進めてきました。
また、研究成果をさらに応用可能な形にするため、複数の共同研究プロジェクトを
開始し、連携を強化しました。一方で、日本の研究力の低下、大学医学部の研究者や
若い医師の不足、次代を担う若手研究者の研究時間の不足など、多くの課題に直面し
ています。医師の働き方改革や研究費の効率的な配分が進む中で、持続可能な研究環
境の構築が一層重要となっています。
そのため、本研究所では、柔軟な働き方を支援する取り組みや、所内外での交流を
活発化させるための施策を推進しています。こうした厳しい環境にもかかわらず、
2023 年度は、基礎研究および臨床研究の分野で多くの質の高い研究成果が発表されま
した。これらの成果は、研究者や技術職員の献身的な努力の賜物であり、所員の奮闘
に深い敬意を表します。
2024 年度以降も、ライフサイエンス研究所では、所員一同が協力し、生命科学の進
展と社会への貢献に向けて努力を続けていく所存です。研究を支える全ての関係者へ
の感謝の意を表しつつ、さらなる発展を目指して取り組んでまいります。
令和5年度ライフサイエンス研究所紀要 研究業績
岡田 斉 （ライフサイエンス研究所所長 兼任 近畿大学 医学部 生化学教室 主任教授）
- Dash S, Ueda T, Komuro A, Honda M, Sugisawa R, Okada H. Deoxycytidine kinase inactivation
enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic
cancer Cell Death Dis. 2024 Feb 12;15(2):131. doi: 10.1038/s41419-024-06531-x.
永井 義隆（ライフサイエンス研究所 副所長 兼任 近畿大学 医学部 内科学教室〔脳神経内科部門〕 主任教授）
- Terayama A, Yoshikawa K, Michiura T, Fujii K, Inada R, Mitsui Y, Nishino I, Nagai Y. A case of
thymoma-associated myasthenia gravis accompanied with myositis showing the clusters of
histiocyte along the fascicles in perimysium Clin Neurol Neurosurg. 2023 Jun;229:107715. doi:
10.1016/j.clineuro.2023.107715. Epub 2023 Apr 11.
- Hirano M, Samukawa M, Isono C, Nagai Y. The effects of safinamide on dysphagia in Parkinson's
disease PLoS One. 2023 May 25;18(5):e0286066. doi: 10.1371/journal.pone.0286066. eCollection
2023.
- Fujino Y, Ueyama M, Ishiguro T, Ozawa D, Ito H, Sugiki T, Murata A, Ishiguro A, Gendron T,
Mori K, Tokuda E, Taminato T, Konno T, Koyama A, Kawabe Y, Takeuchi T, Furukawa Y, Fujiwara
T, Ikeda M, Mizuno T, Mochizuki H, Mizusawa H, Wada K, Ishikawa K, Onodera O, Nakatani K,
Petrucelli L, Taguchi H, Nagai Y. FUS regulates RAN translation through modulating the Gquadruplex
structure of GGGGCC repeat RNA in C9orf72-linked ALS/FTD Elife. 2023 Jul
18;12:RP84338. doi: 10.7554/eLife.84338.
- Saigoh K, Hirano M, Mitsui Y, Oda I, Ikegawa A, Samukawa M, Yoshikawa K, Yamagishi Y,
Kusunoki S, Nagai Y. Memantine administration prevented chorea movement in Huntington's
disease: a case report J Med Case Rep. 2023 Oct 16;17(1):431. doi: 10.1186/s13256-023-04161-z.
- Hirano M, Kuwahara M, Yamagishi Y, Samukawa M, Fujii K, Yamashita S, Ando M, Oka N,
Nagano M, Matsui T, Takeuchi T, Saigoh K, Kusunoki S, Takashima H, Nagai Y. CANVAS-related
RFC1 mutations in patients with immune-mediated neuropathy Sci Rep. 2023 Oct 18;13(1):17801.
doi: 10.1038/s41598-023-45011-8.
- Ito H, Machida K, Hasumi M, Ueyama M, Nagai Y, Imataka H, Taguchi H. Reconstitution of
C9orf72 GGGGCC repeat-associated non-AUG translation with purified human translation factors
Sci Rep. 2023 Dec 20;13(1):22826. doi: 10.1038/s41598-023-50188-z.
- Kakuda K, Ikenaka K, Kuma A, Doi J, Aguirre C, Wang N, Ajiki T, Choong CJ, Kimura Y,
Badawy SMM, Shima T, Nakamura S, Baba K, Nagano S, Nagai Y, Yoshimori T, Mochizuki H.
Lysophagy protects against propagation of α-synuclein aggregation through ruptured lysosomal
vesicles Proc Natl Acad Sci U S A. 2024 Jan 2;121(1):e2312306120. doi: 10.1073/pnas.2312306120.
Epub 2023 Dec 26.
- Hirano M, Samukawa M, Isono C, Kusunoki S, Nagai Y. The effect of rasagiline on swallowing
function in Parkinson's disease Heliyon. 2023 Dec 12;10(1):e23407. doi:
10.1016/j.heliyon.2023.e23407. eCollection 2024 Jan 15.
- Gotoh S, Mori K, Fujino Y, Kawabe Y, Yamashita T, Omi T, Nagata K, Tagami S, Nagai Y, Ikeda
M. eIF5 stimulates the CUG initiation of RAN translation of poly-GA dipeptide repeat protein
(DPR) in C9orf72 FTLD/ALS J Biol Chem. 2024 Mar;300(3):105703. doi:
10.1016/j.jbc.2024.105703. Epub 2024 Jan 30.
- Ueda T, Takeuchi T, Fujikake N, Suzuki M, Minakawa EN, Ueyama M, Fujino Y, Kimura N,
Nagano S, Yokoseki A, Onodera O, Mochizuki H, Mizuno T, Wada K, Nagai Y. Dysregulation of
stress granule dynamics by DCTN1 deficiency exacerbates TDP-43 pathology in Drosophila models
of ALS/FTD Acta Neuropathol Commun. 2024 Feb 4;12(1):20. doi: 10.1186/s40478-024-01729-8.
重吉 康史（ライフサイエンス研究所 教授 兼任 近畿大学 医学部 解剖学教室 主任教授）
- Kanazawa Y, Ikeda-Matsuo Y, Sato H, Nagano M, Koinuma S, Takahashi T, Suzuki H, Miyachi R,
Shigeyoshi Y. Effects of Obesity in Old Age on the Basement Membrane of Skeletal Muscle in Mice
Int J Mol Sci. 2023 May 24;24(11):9209. doi: 10.3390/ijms24119209.
- Kanazawa Y, Takahashi T, Nagano M, Koinuma S, Shigeyoshi Y. The Effects of Aging on
Sarcoplasmic Reticulum-Related Factors in the Skeletal Muscle of Mice Int J Mol Sci. 2024 Feb
10;25(4):2148. doi: 10.3390/ijms25042148.
西尾 和人（ライフサイエンス研究所 ゲノムセンター長 教授 兼任 近畿大学 医学部 ゲノム生物学教室 主任教授）
- Sato H, Murakami K, Fujishima R, Otani T, Sakai K, Nishio K, Matsumura N. Uterine
angioleiomyoma with disseminated intravascular coagulation: a case report BMC Womens Health.
2023 Apr 3;23(1):157. doi: 10.1186/s12905-023-02292-5.
- Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwara T,
Kawakami K, Aomatsu N, Kondoh C, Kawakami H, Takegawa N, Esaki T, Shimokawa M, Nishio
K, Narita Y, Hara H, Sunakawa Y, Boku N, Moriwaki T, Eguchi Nakajima T, Muro K. A Phase II
Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS
Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial Target Oncol.
2023 May;18(3):369-381. doi: 10.1007/s11523-023-00963-9. Epub 2023 May 6.
- Suda K, Sakai K, Ohira T, Chikugo T, Satou T, Matsubayashi J, Nagao T, Ikeda N, Tsutani Y,
Mitsudomi T, Nishio K. Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-
Cell Lung Cancer and Its Potential at Clinical Molecular Screening Cancers (Basel). 2023 May
7;15(9):2648. doi: 10.3390/cancers15092648.
- Takakura T, Kanemura H, Sakai K, Nishio K, Nakagawa K, Hayashi H. Efficacy of Crizotinib
After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
JTO Clin Res Rep. 2023 May 4;4(6):100523. doi: 10.1016/j.jtocrr.2023.100523. eCollection 2023
Jun.
- Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S,
Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto
N, Nakagawa K. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary
Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial Clin Lung Cancer. 2023
Sep;24(6):519-527.e4. doi: 10.1016/j.cllc.2023.05.008. Epub 2023 Jun 3.
- Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka
Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T,
Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Tumor
Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-
Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study
(WJOG11518L:SUBMARINE) J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi:
10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25.
- Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N,
Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N,
Nishio K. Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without
bevacizumab in first-line advanced EGFR(+)non-small-cell lung cancer Transl Lung Cancer Res.
2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13.
- Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R,
Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takeda M, Okuno T, Takegawa N, Haratani K,
Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K. Novel single nucleotide polymorphism
biomarkers to predict opioid effects for cancer pain Oncol Lett. 2023 Jul 4;26(2):355. doi:
10.3892/ol.2023.13941. eCollection 2023 Aug.
- Kamata K, Takenaka M, Nishida N, Hara A, Otsuka Y, Tanaka H, Omoto S, Minaga K, Yamao K,
Chiba Y, Sakai K, Nishio K, Watanabe T, Kudo M. Impact of Smad4 and p53 mutations on the
prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy Int J Clin
Oncol. 2023 Nov;28(11):1511-1519. doi: 10.1007/s10147-023-02396-w. Epub 2023 Aug 18.
- Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, Michiue H, Ichihara E,
Ohashi K, Inoue T, Tamiya M, Sakai K, Ueda Y, Dansako H, Nishio K, Kiura K, Date I, Togashi Y.
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer
immunotherapies Int J Cancer. 2024 Jan 1;154(1):169-179. doi: 10.1002/ijc.34700. Epub 2023 Aug
23.
- Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S,
Nakagawa K. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with
untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3
randomized study) Transl Lung Cancer Res. 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-
736. Epub 2023 Aug 10.
- Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde
Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M,
Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani
N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K. NOTCH1 and
CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected
EGFR-mutated NSCLC: translational research of phase III IMPACT study Mol Oncol. 2024
Feb;18(2):305-316. doi: 10.1002/1878-0261.13542. Epub 2023 Oct 28.
- Tanizaki J, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A, Kitamura Y,
Mamesaya N, Kadota Y, Sawa K, Okishio K, Okada M, Suminaka C, Noda K, Sakai K, Chiba Y,
Nishio K, Chamoto K, Honjo T, Yamamoto N, Nakagawa K, Hayashi H. Lack of Association of
Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and
CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant
Chemotherapy JTO Clin Res Rep. 2023 Oct 13;4(12):100590. doi: 10.1016/j.jtocrr.2023.100590.
eCollection 2023 Dec.
- Pan Y, Suzuki T, Sakai K, Hirano Y, Ikeda H, Hattori A, Dohmae N, Nishio K, Kakeya H.
Bisabosqual A: A novel asparagine synthetase inhibitor suppressing the proliferation and migration
of human non-small cell lung cancer A549 cells Eur J Pharmacol. 2023 Dec 5;960:176156. doi:
10.1016/j.ejphar.2023.176156. Epub 2023 Oct 30.
- Sakamoto S, Ando K, Pae S, Zhao X, Sakai K, Sato K, Saito S, Yamada Y, Rii J, Goto Y, Sazuka
T, Imamura Y, Anzai N, Akakura K, Nishio K, Ichikawa T. Copy Number Gain in Androgen
Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer Anticancer
Res. 2024 Feb;44(2):639-647. doi: 10.21873/anticanres.16853.
- Yoshida T, Sakai K, Kaibori M, Ishida M, Tanaka S, Kubo S, Nakai T, De Velasco MA,
Matsushima H, Tsuta K, Sekimoto M, Nishio K. Downregulated expression of PBRM1 in
sarcomatoid hepatocellular carcinoma Oncol Lett. 2024 Jan 26;27(3):124. doi:
10.3892/ol.2024.14257. eCollection 2024 Mar.
- Takasaki T, Hamabe Y, Touchi K, Khandakar GI, Ueda T, Okada H, Sakai K, Nishio K, Tanabe
G, Sugiura R. ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through
ROS Induction in Melanoma and Pancreatic Cancer Cells Oxid Med Cell Longev. 2024 Mar
11;2024:7683793. doi: 10.1155/2024/7683793. eCollection 2024.
- Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y,
Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T,
Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Association
of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with
unresectable Stage III non-small cell lung cancer Br J Cancer. 2024 May;130(11):1783-1794. doi:
10.1038/s41416-024-02662-2. Epub 2024 Mar 22.
- Arimura A, Sakai K, Kaneshiro K, Morisaki T, Hayashi S, Mizoguchi K, Yamada M, Kai M, Ono
M, Nishio K, Nakamura M, Kubo M. TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as
Prognostic Biomarkers for Primary Triple-Negative Breast Cancer Cancers (Basel). 2024 Mar
18;16(6):1184. doi: 10.3390/cancers16061184.
坂井 和子（ライフサイエンス研究所ゲノムセンター 講師 兼任 近畿大学 医学部 ゲノム生物学教室 講師）
- Koga T, Soh J, Hamada A, Miyano Y, Fujino T, Obata K, Ohara S, Nishino M, Chiba M, Shimoji
M, Takemoto T, Suda K, Sakai K, Sato H, Mitsudomi T. Clinical Relevance of Patient-Derived
Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
JTO Clin Res Rep. 2023 Jul 27;4(9):100554. doi: 10.1016/j.jtocrr.2023.100554. eCollection 2023
Sep.
- Sato H, Murakami K, Fujishima R, Otani T, Sakai K, Nishio K, Matsumura N. Uterine
angioleiomyoma with disseminated intravascular coagulation: a case report BMC Womens Health.
2023 Apr 3;23(1):157. doi: 10.1186/s12905-023-02292-5.
- Suda K, Sakai K, Ohira T, Chikugo T, Satou T, Matsubayashi J, Nagao T, Ikeda N, Tsutani Y,
Mitsudomi T, Nishio K. Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-
Cell Lung Cancer and Its Potential at Clinical Molecular Screening Cancers (Basel). 2023 May
7;15(9):2648. doi: 10.3390/cancers15092648.
- Takakura T, Kanemura H, Sakai K, Nishio K, Nakagawa K, Hayashi H. Efficacy of Crizotinib
After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
JTO Clin Res Rep. 2023 May 4;4(6):100523. doi: 10.1016/j.jtocrr.2023.100523. eCollection 2023
Jun.
- Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S,
Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto
N, Nakagawa K. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary
Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial Clin Lung Cancer. 2023
Sep;24(6):519-527.e4. doi: 10.1016/j.cllc.2023.05.008. Epub 2023 Jun 3.
- Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka
Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T,
Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Tumor
Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed DeathLigand
1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study
(WJOG11518L:SUBMARINE) J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi:
10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25.
- Kamata K, Takenaka M, Nishida N, Hara A, Otsuka Y, Tanaka H, Omoto S, Minaga K, Yamao K,
Chiba Y, Sakai K, Nishio K, Watanabe T, Kudo M. Impact of Smad4 and p53 mutations on the
prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy Int J Clin
Oncol. 2023 Nov;28(11):1511-1519. doi: 10.1007/s10147-023-02396-w. Epub 2023 Aug 18.
- Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, Michiue H, Ichihara E,
Ohashi K, Inoue T, Tamiya M, Sakai K, Ueda Y, Dansako H, Nishio K, Kiura K, Date I, Togashi Y.
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer
immunotherapies Int J Cancer. 2024 Jan 1;154(1):169-179. doi: 10.1002/ijc.34700. Epub 2023 Aug 23.
- Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa
K. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated
metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized
study) Transl Lung Cancer Res. 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-736. Epub
2023 Aug 10.
- Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde
Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M,
Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani
N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K. NOTCH1 and
CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected
EGFR-mutated NSCLC: translational research of phase III IMPACT study Mol Oncol. 2024
Feb;18(2):305-316. doi: 10.1002/1878-0261.13542. Epub 2023 Oct 28.
- Tanizaki J, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A, Kitamura Y,
Mamesaya N, Kadota Y, Sawa K, Okishio K, Okada M, Suminaka C, Noda K, Sakai K, Chiba Y,
Nishio K, Chamoto K, Honjo T, Yamamoto N, Nakagawa K, Hayashi H. Lack of Association of
Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and
CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant
Chemotherapy JTO Clin Res Rep. 2023 Oct 13;4(12):100590. doi: 10.1016/j.jtocrr.2023.100590.
eCollection 2023 Dec.
- Pan Y, Suzuki T, Sakai K, Hirano Y, Ikeda H, Hattori A, Dohmae N, Nishio K, Kakeya H.
Bisabosqual A: A novel asparagine synthetase inhibitor suppressing the proliferation and migration
of human non-small cell lung cancer A549 cells Eur J Pharmacol. 2023 Dec 5;960:176156. doi:
10.1016/j.ejphar.2023.176156. Epub 2023 Oct 30.
- Sakamoto S, Ando K, Pae S, Zhao X, Sakai K, Sato K, Saito S, Yamada Y, Rii J, Goto Y, Sazuka
T, Imamura Y, Anzai N, Akakura K, Nishio K, Ichikawa T. Copy Number Gain in Androgen
Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer Anticancer
Res. 2024 Feb;44(2):639-647. doi: 10.21873/anticanres.16853.
- Yoshida T, Sakai K, Kaibori M, Ishida M, Tanaka S, Kubo S, Nakai T, De Velasco MA,
Matsushima H, Tsuta K, Sekimoto M, Nishio K. Downregulated expression of PBRM1 in
sarcomatoid hepatocellular carcinoma Oncol Lett. 2024 Jan 26;27(3):124. doi:
10.3892/ol.2024.14257. eCollection 2024 Mar.
- Takasaki T, Hamabe Y, Touchi K, Khandakar GI, Ueda T, Okada H, Sakai K, Nishio K, Tanabe
G, Sugiura R. ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through
ROS Induction in Melanoma and Pancreatic Cancer Cells Oxid Med Cell Longev. 2024 Mar
11;2024:7683793. doi: 10.1155/2024/7683793. eCollection 2024.
- Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y,
Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T,
Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Association
of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with
unresectable Stage III non-small cell lung cancer Br J Cancer. 2024 May;130(11):1783-1794. doi:
10.1038/s41416-024-02662-2. Epub 2024 Mar 22.
- Arimura A, Sakai K, Kaneshiro K, Morisaki T, Hayashi S, Mizoguchi K, Yamada M, Kai M, Ono
M, Nishio K, Nakamura M, Kubo M. TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as
Prognostic Biomarkers for Primary Triple-Negative Breast Cancer Cancers (Basel). 2024 Mar
18;16(6):1184. doi: 10.3390/cancers16061184.
武内 敏秀（ライフサイエンス研究所 准教授）
- Fujino Y, Ueyama M, Ishiguro T, Ozawa D, Ito H, Sugiki T, Murata A, Ishiguro A, Gendron T,
Mori K, Tokuda E, Taminato T, Konno T, Koyama A, Kawabe Y, Takeuchi T, Furukawa Y, Fujiwara
T, Ikeda M, Mizuno T, Mochizuki H, Mizusawa H, Wada K, Ishikawa K, Onodera O, Nakatani K,
Petrucelli L, Taguchi H, Nagai Y. FUS regulates RAN translation through modulating the Gquadruplex
structure of GGGGCC repeat RNA in C9orf72-linked ALS/FTD Elife. 2023 Jul
18;12:RP84338. doi: 10.7554/eLife.84338.
- Hirano M, Kuwahara M, Yamagishi Y, Samukawa M, Fujii K, Yamashita S, Ando M, Oka N,
Nagano M, Matsui T, Takeuchi T, Saigoh K, Kusunoki S, Takashima H, Nagai Y. CANVAS-related
RFC1 mutations in patients with immune-mediated neuropathy Sci Rep. 2023 Oct 18;13(1):17801.
doi: 10.1038/s41598-023-45011-8.
- Ueda T, Takeuchi T, Fujikake N, Suzuki M, Minakawa EN, Ueyama M, Fujino Y, Kimura N,
Nagano S, Yokoseki A, Onodera O, Mochizuki H, Mizuno T, Wada K, Nagai Y. Dysregulation of
stress granule dynamics by DCTN1 deficiency exacerbates TDP-43 pathology in Drosophila models
of ALS/FTD Acta Neuropathol Commun. 2024 Feb 4;12(1):20. doi: 10.1186/s40478-024-01729-8.
森 樹史（ライフサイエンス研究所 助手）
- Toriumi K, Onodera Y, Takehara T, Mori T, Hasei J, Shigi K, Iwawaki N, Ozaki T, Akagi M,
Nakanishi M, Teramura T. LRRC15 expression indicates high level of stemness regulated by
TWIST1 in mesenchymal stem cells iScience. 2023 May 23;26(7):106946. doi:
10.1016/j.isci.2023.106946. eCollection 2023 Jul 21. - Mori T, Igarashi M, Onodera Y. Takehara T, Itokazu M, Teramura, T
Fibrinogen supports self-renewal of mesenchymal stem cells under serum-reduced condition through
autophagy activation. Biochem Biophys Res Commun. 2023 Apr 9:651:70-78. doi:
10.1016/j.bbrc.2023.02.009. Epub 2023 Feb 10.
